Role of the COP9 Signalosome in Gastrointestinal Cancers

Sandra Jumpertz1, Jürgen Bernhagen1* and Anke K. Schütz1*

1Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University, Pauwelsstraße 30, 52074 Aachen, Germany

*Corresponding author: Anke K. Schütz, Institute of Biochemistry and Molecular Cell Biology, Pauwelsstraße 30, 52074 Aachen, Germany; Tel: +49 241 80-85096; Fax: +49 241 80-82427; E-mail: anschuetz@ukaachen.de

Jürgen Bernhagen, Institute of Biochemistry and Molecular Cell Biology, Pauwelsstraße 30, 52074 Aachen, Germany; Tel: +49 241 80-88831; Fax: +49 241 80-82427; E-mail: jbernhagen@ukaachen.de

Received date: Sep 11, 2014, Accepted date: Dec 27, 2014, Published date: Dec 30, 2014

Copyright: © 2014 Jumpertz S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The COP9 signalosome (CSN) is an evolutionarily conserved multi-protein complex found in plants and animals. In mammals, the CSN consists of eight subunits (CSN1-CSN8). It has been suggested to play a key role in tumorigenesis, because its subunits are frequently overexpressed in human cancers and because the CSN is involved in the regulation of a number of processes that are relevant to carcinogenesis and cancer progression, e.g. cell cycle control, signal transduction, and apoptosis. The best-studied biochemical function of the CSN is the control of cellular protein stability via the ubiquitin-proteasome system through regulation of cullin-RING E3 ligase (CRL) activity by deNEDDylation of cullins or by the deubiquitination function of the CSN. Through these activities, the CSN regulates the degradation of several tumor suppressors and oncogenes that are degraded by the 26S proteasome. This review summarizes recent findings that support CSN’s role as a potential key player in tumorigenesis in general, but particularly focuses on evidence on the role of the CSN in gastrointestinal cancers. We cover links to tumorigenesis in the liver, stomach, pancreas, and colon, gathering and discussing findings about CSN’s expression and its functional impact on cancer development and progression.

Keywords: COP9 signalosome; CSN; Gastrointestinal cancer; Hepatocellular carcinoma; Gastric cancer; Pancreatic cancer; Colorectal cancer; JAB1; Deneddylation

The COP9 Signalosome (CSN)

The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) is an evolutionarily conserved multi-subunit protein complex that regulates pivotal cellular processes such as the cell cycle and apoptosis, as well as a number of oncogenic signal transduction pathways. In 1996, Chamovitz et al. first purified the COP9 complex from plants and characterized it as a repressor of dark-grown growth patterns, thus the name “constitutive photomorphogenesis” [1]. An orthologous 450-kDa complex consisting of eight proteins was isolated from human erythrocytes and pig spleen two years later and found to contain the protein c-Jun-activation-domain-binding protein-1 (JAB1) [2,3]. JAB1 had been identified independently of the CSN complex and found to facilitate the binding of c-Jun or JunD to AP-1 sites, thereby acting as a co-activator of AP-1-regulated gene transcription [4]. To date, the CSN has been identified in various eukaryotes, including different fungus species [5-8], Caenorhabditis elegans [9], and Droso phila melanogaster [10]. The name "COP9 signalosome" and the nomenclature of its subunits was unified for the different species by Deng and colleagues in 2000, designating the subunits CSN1 to CSN8 according to their molecular weight [11]. While monomeric CSN5/JAB1 can exist independently of the complex, the other CSN subunits are exclusively found in the whole complex or as part of smaller sub-complexes [12-14]. CSN subunits 1, 2, 3, 4, 7 and 8 harbor a so-called PCI (proteasome, COP9 signalosome, translation initiation factor) domain whereas CSN5 and CSN6 contain an MPN (Mpr1p-Pad1-N-terminal) domain instead [15,16]. Sharon et al. developed a model of the CSN complex based on a mass spectrometry approach suggesting that the CSN could be organized in two clusters with CSN1/2/3/8 on one side and with CSN4/5/6/7 forming the other cluster. In this model, the two clusters are connected by a single link constituted by a CSN1-CSN6 axis [13]. During the preparation of this article, the crystal structure of the human CSN was resolved at a resolution of 3.8 Å. The structure gives spectacular insight into the architecture of this protein complex and shows that the PCI proteins form an 18-stranded composite β-sheet at the centre of the complex which has a horseshoe-shaped appearance. Located across the PCI ring is a helical bundle of the CSN subunits with the MPN-containing subunits CSN5 and CSN6 at its core, the latter forming an intimate dimer [17]. Notably, only CSN5 contains a JAMM (Jab1/CSN5 MPN metalloenzyme) motif that is placed within its MPN domain, and which is critical for the Zn2+-dependent metalloproteinase activity of CSN5 [18]. Through this enzymatic activity, the CSN can cleave NEDD8 (neural precursor cell expressed developmentally down-regulated 8)-conjugates from cullin-RING ligases (CRLs), a process named “deNEDDylation” [19, 20]. CRLs are a large family of multi-subunit E3 ubiquitin ligases assembled on a cullin scaffold. By exchange of various substrate-specific, associated F-box proteins, CRLs have a wide variety of substrates which they ubiquitinate for subsequent proteasomal degradation by the 26S proteasome [21]. By the CSN-dependent removal of NEDD8 from cullins, CRLs are inactivated in short term, as evidenced by biochemical in vitro experiments [22,23], whereas in vivo experiments in the context of living cells showed that NEDDylation/deNEDDylation cycles are essential for CRL stability and activity [19]. Together, this indicates that the CSN is an important regulator of protein turnover. Moreover, the CSN regulates other E3 ubiquitin ligases such as MDM2 (mouse double minute 2 homolog) and COP1 (constitutively photomorphogenic 1) that target p53, 14-3-3σ, or c-Jun [24-26]. Additionally, the CSN has been shown to associate with...
The CSN and its Potential Role in Cancer

Cancer diseases still belong to the most challenging human diseases that are associated with high mortality rates and that are difficult to cure with still only limited knowledge about the mechanisms of their development.

The CSN is a potential key player in tumorigenesis and its subunits are often overexpressed in tumors. For example, CSN5/JAB1 is overexpressed in different tumor entities, e.g. neuroblastoma [33], ovarian tumors [34,35], mamba carcinoma [36,37], hepatocellular carcinoma [38,39], pancreatic cancer [40], lung adenocarcinoma [41], or malignant thyroid lymphoma [42]. The CSN5 gene is rarely mutated, but its amplification was identified in hepatocellular carcinoma and breast tumors [39,43]. Protein and mRNA analysis in tumor lysates showed that CSN4 is overexpressed in prostate tumors [44]. An amplification of the CSN6 gene was identified in human breast cancer samples and in 17 breast cancer cell lines, and CSN6 protein levels were higher in human breast tumors compared to normal breast tissue [45]. In addition, higher CSN6 levels were detected in malignant follicular thyroid carcinomas compared to benign thyroid lesions or normal thyroid tissue [45]. In a transcriptomic analysis, CSN5 and CSN6 mRNA levels were shown to be higher in tumors compared to normal tissue for most myelomas as well as in breast cancer and glioblastoma patients [46].

Beyond the altered expression of the CSN and its subunits in tumors, the CSN has an established impact on several important cellular functions that often are dysregulated in tumorigenesis. The CSN is known to be involved in cell cycle and checkpoint control, regulation of proliferation and apoptosis, in the DNA damage repair pathway, and, as discussed above, in the regulation of CRLs and protein degradation. The more general role of the COP9 signalosome in cancer has recently been summarized in a couple of excellent comprehensive reviews. Therefore, we here focus on the CSN and its role in gastrointestinal cancers.

Molecular Pathways Linking the CSN to Tumorigenesis

Since many key oncogenes and tumor suppressor products such as p27, IκBα, c-Jun, p53, COP1, and 14-3-3r are degraded via the ubiquitin-26S-proteasome pathway and are directly or indirectly regulated by the CSN [24, 25, 47-49], it is likely that the CSN plays a key role in cancer through several pathways.

CSN5/JAB1 is known to promote the nuclear export and subsequent degradation of the tumor suppressor p53 [50]. p53 is stabilized and activated upon DNA damage, it induces apoptosis in normal cells and is mutated in most tumors, thus incapable of properly regulating cell survival in tumor cells. Furthermore, p53 is a key effector of the DNA damage response in the cell that counteracts DNA damage generated by chemicals, reactive oxygen species, UV or ionizing radiation. Activation of the DNA damage response results in a delay or arrest of the cell cycle and in checkpoint activation and thereby protects the cell against accumulating mutations [51]. Upon UV-induced DNA damage or replication fork stress due to chemicals, the sensor kinase ATR (ataxia telangiectasia and Rad3-related protein) is activated. ATR subsequently phosphorylates and thereby activates the checkpoint kinase 1 (Chk1). Chk1 is a signal-transducing kinase that has many downstream effectors, e.g. Cdc25, p53, and Cdc45 [52]. The 9-1-1 complex (Rad9-Rad1-Hus1 complex) is loaded onto DNA after genotoxic damage and controls Chk1 phosphorylation. CSN5 was shown to interact with the 9-1-1 complex and to promote its degradation. Thus, CSN5 suppresses checkpoint signaling activation and DNA synthesis recovery after replication stress [53].

The CSN is involved in cell cycle progression at many points. First, CSN5/JAB1 was shown to regulate the CDK-inhibitor p27, promoting its nuclear export and its subsequent degradation – implying a role for the CSN in G1 progression [47]. The E3 ubiquitin ligase SCPSp2 controls G1/S cell cycle regulators including p27 [54]. The CSN regulates SCF ligase activity by its deNEDDylase function, but was shown to regulate Skp2 levels directly as well [55]. In addition, Skp2 forms a complex with Cul4A and DDB1 to target p27 [56]. The reduction of CSN levels causes multiple defects in the cell cycle in a subunit- and tissue-specific manner. Casn5 knockout in T-cells inhibited progression through S phase, but no significant effects on the G1 phase were detected [57]. T-cells with a Casn8 knockout showed defects in the reentry into the cell cycle from the G0 quiescent stage and the CSN was shown to regulate the transcription of the G1 cyclins E, D2 and D3, and of CDK2 and CDK4 [58]. Furthermore, a possible direct link between the CSN and G2/M phase progression could be constituted by the interaction of CSN2 with the anaphase-promoting complex (APC)/cyclosome [59]. Additionally, the interaction between MIF and CSN5 was shown to impair the CSN’s deNEDDylase function, affecting the activity of SCF ligases involved in G2/M checkpoint control [60]. Of note, the CSN has been suggested to play a key role in cell proliferation and maintenance, because the knock out of any Casn subunit tested so far (Casn2, Casn3, Casn5, Casn6, Casn8) led to the death of the respective mice at a very early stage during embryonic development due to defects in cell proliferation and survival [45,58,61-63].

Schweitzer et al. discovered a functional link between the CSN and NF-κB signaling in the cervix carcinoma cell line HeLa. Here, the CSN has been found to control the activity of CRI/Ficus that ubiquitates the NF-κB inhibitor IκBa. Interestingly, the CSN also associated with USP15, thereby promoting IκBa deubiquitination and allowing a precise regulation of NF-κB signaling [27]. A regulative impact of the CSN on NF-κB signaling was also shown in fibroblast cell line HEK293, where the CSN was observed to interact with the IκBa phosphorylating IKK complex and to promote its activity [64]. NF-κB signaling has been mainly associated with inflammatory processes so far, but more and more evidence suggests this signaling pathway to play a key role in tumorigenesis as well and to be an important link of chronic inflammation and cancer [65].

The CSN shows altered expression in different human tumor entities and displays important functions in the cell, implying that the CSN could be a potential target for cancer therapy, although the identified apparent indispensable functions of CSN in cell homeostasis might also contradict this notion. Some of the CSN’s functions are mediated by associated kinases as e.g. CK2α, PKD and IKK2 [64,66]. Interestingly, curcumin effectively inhibits the CSN-associated kinases [67] and is known to be anti-tumorigenic and anti-angiogenic [68,69]. Moreover, especially CSN’s regulatory function on the cellular protein degradation machinery could be an attractive target for cancer therapy, as there are already a couple of proteasome inhibitors in

doi:10.4172/2157-2518.1000210
CSN5 overexpression could drive MYC-dependent transactivation and degradation of the transcription factor for a large variety of genes, thereby promoting transcriptional activity of MYC, but CSN5 also destabilized MYC via the SCF

A search for the CSN5 levels by siRNA knockdown in HepG2 cells resulted in a significant reduction of the CSN5 promotor activity. As expected, PPARγ inhibitor GW9662 was also as effective for knockdown reversed the troglitazone-induced inhibition of the CSN5 promoter activity. Inhibition of HepG2 cell growth after troglitazone treatment was partially rescued by ectopic CSN5 overexpression. Moreover, HepG2 cell xenografts showed a reduced volume and less blood vessels in the tumor microenvironment were detected following troglitazone treatment. In parallel, CSN5 expression and CSN5 protein levels were reduced whereas p27 levels were increased in the HepG2-xenografts, after intratumor injection of troglitazone [38].

Trogilitazone is a peroxisome proliferator-activated receptor γ (PPARY) ligand that exhibits anti-tumoral effects in HCC cells through inhibition of cell proliferation. It leads to an accumulation of p27 and attenuates Skp2 mRNA expression in HCC cells [78, 79]. Interestingly, treatment of HepG2 cells with troglitazone or another PPARγ ligand, rosiglitazone, downregulates CSN5 protein levels and mRNA expression in a dose-dependent manner by inhibition of β-catenin/Tcf4 binding to the CSN5 promotor. As expected, PPARγ inhibitor GW9662 also as well as a PPARγ knockdown reversed the troglitazone-induced inhibition of the CSN5 promoter activity. Inhibition of HepG2 cell growth after troglitazone treatment was partially rescued by ectopic CSN5 overexpression. Moreover, HepG2 cell xenografts showed a reduced volume and less blood vessels in the tumor microenvironment were detected following troglitazone treatment. In parallel, CSN5 expression and CSN5 protein levels were reduced whereas p27 levels were increased in the HepG2-xenografts, after intratumor injection of troglitazone [38].

Topoisomerase II α (topoIIα), an enzyme that loosens up the DNA helix to allow transcription, was found to be overexpressed in HCC and to be associated with chemoresistance [80]. HDAC (histone deacetylase) inhibitors, e.g. AR42 or MS-275, facilitate topoIIα proteolysis through transcriptional activation of the topoIIα-phosphorylating enzyme CK2α (casein kinase 2α) by increasing the association of acetylated histone H3 with the CK2α promotor [81, 82].

Role of the CSN in Hepatocellular Carcinoma and in the Liver

Liver cancer is the fifth most common cancer in men and ranks seventh in prevalence for cancers in women. Because of its high fatality (ratio of mortality to incidence) it is the third most common cause of death from cancer worldwide [72]. Hepatocellular carcinoma (HCC) is widespread in Asia and Africa, due to frequent hepatitis B or C infections in these countries. In the Western world, HCC mostly results from liver fibrosis and liver cirrhosis [73]. In an array-based comparative genomic hybridization analysis of HCC patient samples, a copy number gain of chromosome 8q, encoding CSN5, was observed in 39% of the cases [39]. In parallel, high CSN5 expression was detected in these HCC samples compared to normal tissue. By immunohistochemical staining, Patil et al. identified 40% of the HCC samples to have CSN5-positive nuclei, while they did not detect CSN5 in normal hepatocytes [39]. Of note, Hsu et al. found that CSN5 overexpression in HCC tissue samples correlates with female gender and hepatitis C infection [38]. Further, CSN5 expression was monitored in developing HCC; CSN5 overexpression occurs in early stages of hepatocarcinogenesis and is significantly associated with an expression of MYC-regulated target genes [74]. This could imply that CSN5 may play a crucial role in liver cancer progression by transcriptional activation of MYC target genes. MYC serves as a transcription factor for a large variety of genes, thereby promoting proliferation, apoptosis, differentiation, metabolism, and genome stability, and is frequently overexpressed in many human cancers [75]. Association of MYC and CSN5 was described in breast cancer, where CSN5 promotes transcriptional activity of MYC, but CSN5 also destabilized MYC via the SCF [70••]. Besides, a CSN5 knockdown in HuH7 HCC cells resulted in a significant downregulation of 83 genes that were also significantly elevated in early HCC in comparison to dysplastic nodules [76]. In the downregulation of anti-apoptotic Bcl-2 and in increased levels of pro-apoptotic Bak. Of note, loss of CSN5 resulted in a decrease of Skp2 that is part of a CRL and induces the degradation of the CDK inhibitors p21 and p27 in HuH7 and HepG2 cells. In parallel, an accumulation of p27 and of the tumor suppressor p53 was observed in HepG2 cells after CSN5 depletion [77].

To address CSN5 as a potential target for HCC therapy, CSN5 siRNA – encapsulated in SNALPs (stable-nucleic-acid-lipid particles) and modified with 2′-O-Methyl or with guanosine nucleosides, was given to mice with HuH7 cell tumors growing in their livers. The mice treated with the siRNA specific for CSN5 had smaller tumors and an improved well-being compared to control mice, indicating that CSN5 is an important player in HCC growth and might indeed be a promising target in HCC therapy [77].

Clinical trials and in clinical use. The list encompasses Bortezomb, Carfilzomib, NPI-0052, MLN9708, CEP-18770, ONX0912, and Marizomib. Bortezomib is a peptide boronate inhibitor that binds specifically the catalytic site of the 26S proteasome. It is approved for the treatment of multiple myeloma since several years and its application significantly improved the prognosis of multiple myeloma patients [70,71].
Role of the CSN in Gastric Cancer

About one million new cases of stomach cancer were estimated to have occurred in 2008, making it currently the fourth most common malignancy in the world. Gastric cancer is the second leading cause of cancer-related deaths worldwide and its development is very often associated with a Helicobacter pylori infection [72,87]. Recently, gene expression profiling of gastric carcinoma patient samples combined with a bioinformatic analysis revealed that CSN5 and CSN6 are significantly upregulated in gastric carcinoma. Furthermore, the transcription factors MYC and MAZ (MYC-associated zinc-finger protein) showed a similar expression profile as these CSN subunits and were significantly enriched [88].

RUNX3 (Run-related transcription factor 3) is known to be a strong tumor suppressor in gastric cancer as well as in several other cancer entities. In gastric cancer, the expression of RUNX3 is frequently lost as a result of promotor hypermethylation, and RUNX3 is often inactivated by mislocalization in the cell [89,90]. Interestingly, CSN5 and RUNX3 interact in SNU53 cells, a human gastric cancer cell line, and in HEK293 cells. CSN5’s MPN domain and RUNX3’s Runt domain were identified to be essential for this interaction. Overexpression of CSN5 resulted in lower RUNX3 levels, an effect that is inhibited by the proteasome inhibitor MG132. As expected, a knockdown of CSN5 led to an increase of RUNX3 in HEK293 cells. In parallel, CSN5 affected p21 levels – p21 is a target protein of RUNX3 and a cyclin-dependent kinase inhibitor. In addition, CSN5’s MPN domain and its NES region were identified to be essential for the nuclear export and degradation of RUNX3. The nuclear export of RUNX3 is facilitated by CSN5, but is also CRM1 (chromosome region maintenance 1)-dependent. Furthermore, the CSN-associated kinase CK2α was shown to support the CSN5-mediated degradation of RUNX3 [91].

MicroRNA-146a (miR-146a) is a modulator of inflammatory signals and was found upregulated in a mouse model of gastric cancer, i.e. the Gastrin knockout mouse, and in 2/3 of human gastric adenocarcinomas [92]. In this study, CSN8 and CARD10 (caspase recruitment domain-containing protein 10) were identified as new targets of miR-146a. CSN8, CARD10 and IRAK1 – a known miR-146a target – all belong to signaling pathways leading to NF-κB activation and were all down-regulated after overexpression of miR-146a in SNU638 gastric cancer cells [92]. NF-κB activation is associated with inflammation-mediated gastric carcinogenesis and with gastric cancer cell migration and invasion [93,94]. The CSN is known to control NF-κB activity by deubiquitination of its inhibitor IκBα – mediated by the CSN-associated deubiquitinate USP15, and by maintaining the activity of IκBα ubiquitin ligase SCFβTrCP through its deNEDDylase function [27,29,64,95]. Crone et al. suggest the miR-146a levels to be upregulated by NF-κB activity in a negative feedback loop and determined NF-κB activation to be inhibited by overexpression of miRNA-146a in SNU638 cells. Furthermore, CSN2 was found to be down-regulated in this model, indicating that the CSN might be destabilized by miRNA-146a. Notably, the knockdown of CSN8, CSN2 or CSN5 in SNU638 cells inhibited GPCR-mediated activation of NF-κB comparable to the miR-146a-induced effect [92].

p57 is a CDK inhibitor and its mRNA levels were shown to be very low in gastric cancer cells [96,97]. It shares sequence similarity with p27 and its overexpression causes complete cell cycle arrest in G1 phase [98]. Degradation of p57 is mediated by SCFSkp2-dependent ubiquitylation [99]. Of note, recently it was shown that Skp2 depletion inhibits growth and metastasis of gastric cancer cells by inducing cell cycle arrest in the G1/S phase, paralleled by upregulation of p57 [100].

CSN6 overexpression resulted in decreased p57 levels and in an accelerated proteasomal degradation of p57 in HEK293 cells. There are hints that CSN6, p57 and Skp2 might form common complexes in the cell, and p57 degradation was shown to be Skp2-dependent [101], indicating that the CSN might associate with SCFSkp2 E3 ligase to promote p57 ubiquitination and degradation. Thus, one might speculate that CSN(6) promotes the degradation of the CDK inhibitor p57 in gastric cancer cells to promote gastric tumor growth and metastasis.
To date, there are just a few studies addressing CSN’s potential role in gastric cancer development, but there are strong hints that the CSN is not just overexpressed in stomach cancer. It rather functionally affects the tumor suppressor RUNX3, the cell cycle regulators p21 and p57 in gastric cancer cells, and it is associated with gastric inflammation by its effect on NF-κB signaling. Altogether, this suggests that the CSN may have an important supportive function in gastric tumorigenesis.

Role of the CSN in Pancreatic Carcinoma

Pancreatic cancer resulted in about 330,000 deaths worldwide in 2012 and is thus currently the seventh most common cause of deaths due to cancer [102]. Known risk factors for pancreatic cancer, amongst others, are smoking, obesity and diabetes [103, 104]. Pancreatic cancer often has very poor outcomes – 5-year-survival is estimated to be only 5% – due to a lack of symptoms in the early phase of the disease and thereby mostly late diagnosis, when the tumor cells have already metastasized [102].

CSN5 was shown to be overexpressed in pancreatic adenocarcinoma compared to normal pancreatic tissue [40, 105]. In 27 human pancreatic adenocarcinoma cell lines, distinct high-level amplifications of chromosome 7q22 that encodes CSN6, were identified [106]. CSN5 overexpression was found to correlate with absent or low expression of p27 in pancreatic adenocarcinoma samples, and low p27 levels are associated with a poor prognosis for patients with pancreatic cancer [40, 105]. In most of the tumors, the staining for CSN5 was predominantly nuclear with a weaker cytoplasmic staining [105]. This inverse correlation of CSN5 and p27 can be explained by CSN5’s role in promoting nuclear export and subsequent degradation of p27 [47, 107]. In fact, enhancement of proteasomal degradation of p27 by CSN5 was seen in different pancreatic cancer cell lines, i.e. Panc-1, Mia PaCa-2, Panc-28. Additionally, a direct interaction between p27 and CSN5 was uncovered in a GST-pulldown assay and confirmed in Panc-1 and Panc-28 cells. As expected, a knockdown of CSN5 in the three mentioned pancreatic cancer cell lines resulted in an accumulation of p27 and an associated cell cycle arrest. Of note, in Panc-28 cells, it was shown that CSN5’s effect on p27 degradation was Skp2-independent [105], p27 degradation is known to be mediated by ubiquitin E3 ligation $\text{SCF}_{\text{CSN5}}$ [108], but recently an alternative E3 ubiquitin ligase, i.e. SIAH-1 (seven in absentia homolog-1), that is regulated by CSN5, was shown to interact with p27 and to regulate its stability [109-111]. Furthermore, p8 is known to facilitate the translocation of p27 from the nucleus to the cytoplasm that is mediated by CSN5, and p8 and CSN5 were shown to directly interact [112]. p8 is a stress-inducible protein that is known to be overexpressed in stressed pancreatic tissue, in chronic pancreatitis, and in pancreatic cancer [113, 114].

SMAD4 is a mediator of TGFβ signaling, which regulates growth and differentiation, normally acts as a tumor suppressor, and was shown to be mutated or even inactivated in half of pancreatic cancers [115]. SMAD4 protein levels appear low in human pancreatic ductal adenocarcinoma [116], and SMAD4 inactivation has been suggested to be a key event during pancreatic tumorigenesis [117]. Remarkably, CSN5 promotes SMAD4 degradation in pancreatic cancer cell lines Panc-1 and AsPC-1 via SCF$\text{CSN5}$ E3 ubiquitin ligase [116, 118]. Point-mutated SMAD4, typically found in pancreatic adenocarcinoma, showed an increased affinity to the F-box protein βTrCP; thus its degradation that is additionally promoted by high CSN5 levels, is potentially enhanced in pancreatic tissue [116].

As already discussed for HCC, the interplay between MYC and CSN5 might play a key role in pancreatic cancer as well. In Mia PaCa-2 and Panc-1 cells, knockdown of $\text{CSN5/βTRCP}$ impaired cell proliferation and enhanced apoptosis – independent of the p53 status of the cells. These CSN5-depleted cells showed increased MYC levels and an additional depletion of MYC rescued cells from growth suppression [119].

Interestingly, Li et al. tested PEGylated curcumin, an inhibitor of the CSN-associated kinases, and asked if it inhibited cell growth of pancreatic cancer cells, and thus if it might be a potential future therapeutic for pancreatic cancer. PEG (polyethylene glycol)-ylation makes curcumin, that is known to be anti-tumorigenic, water-soluble and thereby facilitates its delivery. In this study, (PEG-)curcumin inhibited cell growth of pancreatic Panc-1, Mia PaCa-2, BxPC-3, and AsPC-1 cells in a dose-dependent manner. Additionally, the CRL targets p27 and SMAD4 were upregulated after (PEG-)curcumin treatment in Panc-1 and AsPC-1 cells, indicating that CSN’s activity is inhibited. Of note, PEG-curcumin sensitized pancreatic cancer cells to gemcitabine-induced apoptosis and inhibition of cell proliferation [120]; this supports the hypothesis that the CSN and its associated kinases are promising targets in future pancreatic cancer therapy.

Together, in pancreatic tissue the CSN regulates the cell cycle by its close association with p27; it also affects TGFβ signaling and the tumor suppressor SMAD4, and functionally interacts with the oncogene MYC. As shown by Li et al., an inhibition of CSN activity or its associated kinases might have a therapeutic benefit for pancreatic cancer patients.

Role of the CSN in Colorectal Carcinoma

Colorectal cancer (CRC) is the third most common cancer in men and the second most prevalent one in women worldwide, resulting in about 608,000 deaths related to CRC in 2008 [72]. CRC is a very common form of cancer in the Western world due to lifestyle habits as smoking, excessive alcohol use or obesity, which are known risk factors. Diagnosis is often delayed; consequently, CRC is one of the deadliest forms of cancer.

To date, there are just a few studies that have addressed the expression and the potential role of the CSN in colorectal carcinoma. A recent study showed that 70% of the patients with colon adenocarcinoma have significantly higher CSN5 mRNA levels in the tumor tissue compared to surrounding normal tissue, and that 40% of them have significantly higher CSN6 mRNA levels in their tumors [46]. Next to this expression study, there are first hints from in vitro studies that the CSN has a functional impact on CRC cell behavior and that it might contribute to the development of the ‘hallmarks’ of this cancer entity. Schütz et al. showed that the reduction of CSN5 levels correlated with a reduction of CSN1 and CSN8 protein levels in SW480 CRC cells, and that the proliferation rate of different CRC cell lines (SW480, HCT116, HT29, CaCo2) was reduced after CSN5 knockdown. Surprisingly, also the rate of apoptosis after etoposide treatment was reduced by CSN5 knockdown in HCT116 cells [121]. During CRC tumorigenesis, mutations or deletions of a number of tumor suppressor genes and oncopgenes accumulate [122]. CRC development is often associated with mutations of the Wnt signaling pathway. Mostly, the APC gene is mutated, but mutations in β-catenin/CTNNB1 are also observed in CRC [123, 124].

In normal cells, β-catenin levels are tightly regulated by a cytoplasmic destruction complex mainly consisting of APC, Axin, and...
The CSN was shown to affect the protein levels of β-catenin in CRC cells. After knockdown of CSN5, (phospho-)β-catenin levels were reduced in HeLa and SW480 cells, indicating that the CSN might somehow ‘stabilize’ β-catenin. However interestingly, in SW480 cells, CSN5 was shown to also promote short-term β-catenin degradation in a cycloheximide assay [121]. Similar results were obtained with a knockdown of CSN7 that resulted in a retarded degradation of β-catenin in HeLa cells [126]. Additionally, a knockdown of CSN5 resulted in reduced Wnt/β-catenin target gene expression in HCT116 cells, as shown for Axin2, MYC, CD44 and BMP4, indicating that indeed, functional Wnt signaling is affected [110]. In line with this notion, Xin et al. observed reduced COX-2 protein levels in HT29 cells after knockdown of CSN5 [127]. COX-2 is a Wnt target gene that is upregulated in CRC and contributes to its formation. It induces angiogenesis, inhibits apoptosis and promotes tumor cell invasiveness. Of note, COX-2 inhibitors are already used for CRC prevention in FAP (familial adenomatous polyposis) patients [128,129].

The effect of CSN5 on β-catenin could be an effect on the canonical Wnt pathway and associated β-catenin degradation. For example, the CSN, through its deNEDDylase function, might regulate the activity of the E3 ligase CRL3[βTrCP], which is responsible for the ubiquitination of β-catenin. Alternatively, it was shown that a knockdown of CSN7 in HeLa cells resulted in an accelerated degradation of APC, indicating that the canonical degradation of β-catenin might be impaired due to the reduced APC levels following reduction of the CSN. Furthermore, CSN-associated USP15 stabilized APC and thus might destabilize β-catenin in HeLa cells [126]. Huang et al. performed density-gradient centrifugation experiments and found that CSN3, β-catenin, and cullin-1 co-sedimented in the same fractions. By FLAG-pull-downs, they also precipitated CSN2 together with components of the β-catenin destruction complex and of CRL3[βTrCP] and proposed the formation of a β-catenin-degrading super-complex containing the 26S proteasome, CRL3[βTrCP], the canonical β-catenin destruction complex, and the CSN [126].

On the other hand, it was recently shown that CSN5 affects SIAH-1, a key mediator of an alternative β-catenin degradation pathway [110]. SIAH-1 is induced by p53 and forms an alternative degradation complex for β-catenin together with SIP, SKP1, and EBI [130,131], and was shown to promote β-catenin degradation in HCT116 and other cells [110,131]. Of note, in HCT116 CRC cells, CSN5 was shown to affect SIAH-1 protein levels, as after CSN5 knockdown SIAH-1 levels were reduced and, vice versa after CSN5 overexpression, SIAH-1 levels were elevated. CSN5 promoted SIAH-1 expression and SIAH-1 protein degradation – presumably by its deNEDDylase activity. SIAH-1, β-catenin and CSN5 potentially form common protein complexes and thus might also functionally interact as indicated by SIAH-1/CSN5-double-knockdown experiments with an analysis of Wnt target gene expression [110]. Recently, Tanaka et al. determined Sec6, a component of the exocyst complex, to interact with SIAH-1 and CSN5 in HEK293 cells. Sec6 was shown to regulate the cytoplasmic translocation of p27 and to promote its degradation [109]. Thus, the interplay between CSN(5) and SIAH-1 might be essential for the regulation of β-catenin and p27 levels, and thereby might affect cell cycle regulation and proliferation of cancer cells.

Figure 1: Proteins and their associated cellular processes affected by the COP9 signalosome in gastrointestinal cancers. Proteins depicted as circles are arranged according to their related cellular processes, divided into six categories: cell cycle, angiogenesis, inflammation, proliferative signaling, apoptosis and invasion, which are reflecting the hallmarks of cancer to a large part. Proteins located at the border of two categories were found to play a role in both cellular processes. For reasons of clarity, COX-2, NF-κB, and p53, which are related to multiple processes, are depicted twice. Abbreviations: CycD1 (Cyclin D1), topoIIA (topoisomerase IIa), COX-2 (cyclooxygenase-2), NF-κB (nuclear factor κB), MYC (v-myc avian myelocytomatosis viral oncogene homolog), SIAH-1 (seven in absentia homolog-1), SMAD2/3/4 (small mothers against decapentaplegic 2/3/4), RUNX3 (Runt-related transcription factor 3).
In a more general sense, whereas others appear to be more specific for a small but significant decrease of p53 levels in SW480 cells [121]. However, in a recent study no significant effect of CSN5 on prognosis. According to these data, one would expect high CSN5 levels in CRC tumors to correlate with low p27 levels and with a poor prognosis. However, in a recent study no significant effect of CSN5 on p27 protein levels in SW480 CRC cells was observed [121], and to our knowledge there is no study indicating the otherwise established p27-CSN5 correlation would be relevant for CRC development.

Loda et al. correlated a lack of p27 in colorectal carcinoma to a poor survival prognosis compared to CRC patients whose tumors expressed p27 [135]. For breast and pancreatic cancer, it was shown that the expression of CSN5 negatively correlated with the levels of p27 [36, 37, 105]. According to these data, one would expect high CSN5 levels in CRC tumors to correlate with low p27 levels and with a poor prognosis. However, in a recent study no significant effect of CSN5 on p27 protein levels in SW480 CRC cells was observed [121], and to our knowledge there is no study indicating the otherwise established p27-CSN5 correlation would be relevant for CRC development.

In summary, the CSN and in particular its subunit CSN5 affects many key effectors and signaling pathways in cancer cells. Some of these effects as outlined in this review article are presumably relevant in a more general sense, whereas others appear to be more specific for a certain tissue, cell type, or tumor entity.

In colorectal cancer, the CSN might be a key player as well driving tumorigenesis, because it affects signaling pathways that are crucial for CRC development, such as the Wnt signaling pathway, and is involved in β-catenin degradation. Similarly, CSN5 depletion results in reduced proliferation of CRC cells, and, as the CSN is an important player in the DNA damage response, it might be a promising therapeutic target for CRC therapy, e.g. in combination with mitomycin C chemotherapy. On the other hand, it should be kept in mind that evidence linking the CSN to CRC has mainly been in vitro so far.

**Conclusion**

A number of studies over the last several years have established a likely functional role of the COP9 signalosome in several gastrointestinal cancers, i.e. HCC, pancreatic cancer, gastric cancer, and CRC (summarized in table 1). There is strong evidence that the CSN plays a key role in regulating the cell cycle, proliferation, and apoptosis, and there are hints that the CSN also affects additional key processes driving tumorigenesis including angiogenesis, invasion, and chronic inflammation (Figure 1). Whether the CSN also supports the acquisition of further hallmarks of cancer, e.g. metastasis, replicative immortality, or deregulation of cellular energetics, needs to be elucidated. As outlined in this review article, the CSN affects different cellular signaling pathways such as Wnt, TGFβ, and NF-κB signaling and regulates the protein levels of important tumor suppressors. Overall, the described functions of the CSN seem to be in line with a pro-tumorigenic phenotype, as e.g. shown in many tumors after overexpression of different CSN subunits. Moreover, in preclinical in vivo models, a reduction of the CSN resulted in reduced tumor volume and less blood vessels, pointing to a potential therapeutic benefit of agents that reduce CSN protein levels and/or inhibit its functions in tumors. Thus, the CSN might be an interesting target for future therapeutic approaches for the treatment of cancer, while care needs to be taken to not interfere with its inherently crucial functions in cellular physiology.

<table>
<thead>
<tr>
<th>Organ / tumor entity</th>
<th>CSN subunit</th>
<th>Cancer (cell) type</th>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>CSN3</td>
<td>SMMC-7721 and Hep3B cells</td>
<td>CSN3 promotes proliferation, anchorage-independent growth, cell cycle and DNA-synthesis and counteracts apoptosis</td>
<td>[84]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Xenograft mouse model (SMMC-7721 cells)</td>
<td>CSN3 knockdown reduces tumor growth and weight</td>
<td>[84]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Human HCC tissue samples</td>
<td>CSN3 is overexpressed and accumulates in the nucleus</td>
<td>[84]</td>
</tr>
<tr>
<td></td>
<td>CSN5</td>
<td>Hep3B, HuH7, HepG2, HuH1 and PLC/PRF/5 cells</td>
<td>CSN5 promotes cell proliferation</td>
<td>[39,77]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Huh7 and HepG2 cells</td>
<td>CSN5 facilitates cell cycle and counteracts apoptosis, decreases phosphorylation of SMAD2 and SMAD3 (key mediators of TGFβ signaling) and enhances NF-κB p65 levels</td>
<td>[77]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Huh7 cells</td>
<td>CSN5 siRNA encapsulated in SNALP impairs survival</td>
<td>[77]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HuH7 cells</td>
<td>CSN5 knockdown downregulates 83 genes shown to be elevated in early HCC</td>
<td>[74]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HepG2 cells</td>
<td>PPARγ ligands downregulate CSN5 protein levels and mRNA expression</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PLC5 cells</td>
<td>CSN5 promotes the HDAC inhibitor-induced degradation of topoisomerase IIα by CRL5</td>
<td>[82]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Xenograft mouse model (HepG2 cells)</td>
<td>PPARγ ligand treated tumors are smaller and have less blood vessels, correlating with increased expression of CSN5 and p27</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Xenograft mouse model (HuH7 cells)</td>
<td>CSN5 siRNA encapsulated in SNALP decreases tumor growth and improves well-being of the animals</td>
<td>[77]</td>
</tr>
<tr>
<td>Tissue/Microenvironment</td>
<td>Gene</td>
<td>Cell Line</td>
<td>Effect/Observation</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Human HCC tissue samples</td>
<td>CSN5</td>
<td></td>
<td>Chromosome 8q, encoding CSN5, gains copy number in 39% of samples, nuclear CSN5 levels are enhanced.</td>
<td>[39]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CSN5 overexpression correlates with female gender and hepatitis C viral infection</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CSN5 overexpression occurs in early stages of hepatocarcinogenesis and is associated with expression of MYC-regulated target genes</td>
<td>[74]</td>
</tr>
<tr>
<td>Stomach</td>
<td>CSN2</td>
<td>SNU638 cells</td>
<td>CSN2 knockdown inhibits GPCR-mediated NF-κB activation</td>
<td>[92]</td>
</tr>
<tr>
<td></td>
<td>CSN5</td>
<td>SNU638 cells</td>
<td>CSN5 knockdown inhibits GPCR-mediated NF-κB activation</td>
<td>[92]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SNU5 cells</td>
<td>CSN5 interacts with RUNX3</td>
<td>[136]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Human gastric carcinoma tissue samples</td>
<td>Enhanced levels of CSN5 correlate with CSN6 levels and MYC and MAZ expression</td>
<td>[88]</td>
</tr>
<tr>
<td></td>
<td>CSN6</td>
<td>Human gastric carcinoma tissue samples</td>
<td>Enhanced levels of CSN6 correlate with CSN5 levels and MYC and MAZ expression</td>
<td>[88]</td>
</tr>
<tr>
<td></td>
<td>CSN8</td>
<td>SNU638 cells</td>
<td>Overexpression of miRNA-146a downregulates CSN8 and CARD10</td>
<td>[92]</td>
</tr>
<tr>
<td>Pancreas</td>
<td>CSN5</td>
<td>Mia PaCa-2, Panc-28 and Panc-1 cells</td>
<td>CSN5 facilitates p27 degradation</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panc-28 and Panc-1 cells</td>
<td>CSN5 interacts with p27</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mia PaCa-2 and Panc-28 cells</td>
<td>CSN5 promotes cell cycle progression</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panc-28 cells</td>
<td>CSN5-dependent degradation of p27 might be Skp2-independent</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panc-1 and AsPC-1 cells</td>
<td>CSN5 promotes SMAD4 degradation via SCFβTrCP</td>
<td>[116,118]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mia PaCa-2 and Panc-1 cells</td>
<td>CSN5 promotes cell proliferation and inhibits apoptosis via MYC</td>
<td>[119]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panc-1 and AsPC-1 cells</td>
<td>PEGylated curcumin (CSN-associated kinase inhibitor) promotes apoptosis following gemcitabine treatment, inhibits cell growth via decelerating cell proliferation and increases levels of CSN5 degradation targets p27 and SMAD4</td>
<td>[120]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mia PaCa-2 cells</td>
<td>PEGylated curcumin inhibits cell growth via decelerating proliferation</td>
<td>[120]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BxPC-3 cells</td>
<td>PEGylated curcumin inhibits cell growth</td>
<td>[120]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pancreatic adenocarcinoma tissue samples</td>
<td>CSN5 is overexpressed in tumors, mainly in the cytoplasm; patients with p27-positive tumors had a significant better prognosis than those with p27-negative tumors, and p27 localized exclusively in the nucleus further improved their prognosis</td>
<td>[40]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pancreatic adenocarcinoma tissue samples</td>
<td>CSN5 is overexpressed and inversely correlates with p27 levels; in 72% of the tumors predominant nuclear staining for CSN5; tumors with predominant cytoplasmic CSN5-staining were all p27-negative and had a higher proliferation index than cells with predominant nuclear CSN5-staining</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td>CSN6</td>
<td>Pancreatic adenocarcinoma tissue samples</td>
<td>High-level amplifications of chromosome 7q22, encoding CSN6</td>
<td>[106]</td>
</tr>
<tr>
<td>Colon</td>
<td>CSN5</td>
<td>SW480 cells</td>
<td>CSN5 knockdown reduces [phospho]-β-catenin, CSN1, CSN8, and p53 protein levels, and decelerates proliferation</td>
<td>[121]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HCT116 cells</td>
<td>CSN5 promotes apoptosis after etoposide treatment and enhances proliferation</td>
<td>[121]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HCT116 cells</td>
<td>CSN5 promotes expression of Wnt/β-catenin target genes and of SIAH-1, but also supports SIAH-1 degradation, depending on Cullin1-NEDDylation</td>
<td>[110]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HT29 cells</td>
<td>CSN5 knockdown affects COX-2 protein levels</td>
<td>[127]</td>
</tr>
</tbody>
</table>
Table 1: Summary of functional evidence for a role of the CSN in gastrointestinal tumorigenesis.

Table: 
<table>
<thead>
<tr>
<th>HT29 cells</th>
<th>CSN5 promotes proliferation</th>
<th>[121]</th>
</tr>
</thead>
<tbody>
<tr>
<td>CaCo2 cells</td>
<td>CSN5 promotes proliferation</td>
<td>[121]</td>
</tr>
<tr>
<td>Colon adenocarcinoma tissue samples</td>
<td>Higher CSN5 mRNA levels in 70% of the tumor samples compared to normal tissue</td>
<td>[46]</td>
</tr>
<tr>
<td>CSN6 Colon adenocarcinoma tissue samples</td>
<td>Higher CSN6 mRNA levels in 40% of the tumor samples compared to normal tissue</td>
<td>[46]</td>
</tr>
</tbody>
</table>

Acknowledgements

We are indebted to numerous colleagues for inspiring and helpful discussions and apologize to the many colleagues and scientists in the field whose work we were not able to cite due to space constraints.

Financial support

This work was funded by a START-Up grant of the DFG excellence program of RWTH Aachen University (grant 351400) and a START grant of RWTH Aachen University Medical School (grant 690644) to A.K.S., by the START consortium grant 69605-5/project P6 of RWTH Aachen University Medical School to J.B., and by the IZKF Aachen grant SP/O-3 to J.B.

References


